Ivermectin + Balstilmab + Pembrolizumab
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anatomic Stage IV Breast Cancer AJCC v8
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Trial Timeline
Oct 13, 2023 → Oct 1, 2026
NCT ID
NCT05318469About Ivermectin + Balstilmab + Pembrolizumab
Ivermectin + Balstilmab + Pembrolizumab is a phase 1/2 stage product being developed by Agenus for Anatomic Stage IV Breast Cancer AJCC v8. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05318469. Target conditions include Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma.
Hype Score Breakdown
Clinical
9
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05318469 | Phase 1/2 | Recruiting |
Competing Products
13 competing products in Anatomic Stage IV Breast Cancer AJCC v8
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Niraparib Tosylate Monohydrate | Eli Lilly | Phase 1 | 29 |
| Capivasertib + Ceralasertib + Durvalumab + Olaparib + Selumetinib | AstraZeneca | Phase 2 | 27 |
| Pembrolizumab + Tamoxifen + Vorinostat | Merck | Phase 2 | 27 |
| Carboplatin + Docetaxel + Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab + Tucatinib | Novartis | Phase 1/2 | 39 |
| Lutetium Lu 177 Dotatate | Novartis | Phase 2 | 42 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Paclitaxel + Talimogene Laherparepvec + Tamoxifen + Nab paclitaxel + Gemcitabine + Carboplatin | Amgen | Phase 1 | 29 |
| Sacituzumab Govitecan | Gilead Sciences | Phase 2 | 39 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Tamoxifen | Pfizer | Phase 2 | 35 |
| Abexinostat Tosylate + Fulvestrant + Palbociclib | Pfizer | Phase 1 | 21 |
| Aromatase Inhibition Therapy | Bristol Myers Squibb | Pre-clinical | 33 |
| Pelareorep + Retifanlimab | Incyte | Phase 2 | 36 |
| Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody | Imugene | Phase 1 | 23 |
| Neratinib | Puma Biotechnology | Phase 2 | 32 |